Lexicon Pharmaceuticals, Inc. (LXRX)

Oncology Corporate Profile

Stock Performance

14.4000
0.0000

HQ Location

8800 Technology Forest Place
The Woodlands, TX 77381

Company Description

Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism.

Website: http://www.lexpharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
telotristat etiprate / LX1032tryptophan hydroxylase inhibitorVarious cancer typesIII

View additional information on product candidates here »

Source


http://www.lexpharma.com

Recent News Headlines

Lexicon To Present At The Barclays Global Healthcare Conference

3/9/2017 01:00 pm

[PR Newswire] - THE WOODLANDS, Texas, March 9, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 3:50 p.m. Eastern Time in Miami. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercializing XERMELO™ (telotristat ethyl), the first drug from its discovery platform to receive FDA approval, for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in neuropathic pain, diabetes and metabolism.

Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference

3/6/2017 10:03 pm

[PR Newswire] - THE WOODLANDS, Texas, March 6, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, March 8, 2017 at 8:00 a.m. Eastern Time in Boston. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercializing XERMELO™ (telotristat ethyl), the first drug from its discovery platform to receive FDA approval, for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in neuropathic pain, diabetes and metabolism. For additional information please visit www.lexpharma.com.

Lexicon reports 4Q loss

3/3/2017 12:01 pm

Lexicon reports 4Q loss

3/3/2017 12:01 pm

Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results

3/3/2017 12:00 pm

[PR Newswire] - THE WOODLANDS, Texas, March 3, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2016 and provided an ...

Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Dynavax Technologies and Lexicon Pharmaceuticals

3/2/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 2, 2017 / U.S. markets rocketed to record highs Wednesday as President Trump's speech to Congress provided an optimistic view for the U.S. economy and as Federal Reserve ...

Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017

3/1/2017 09:03 pm

[PR Newswire] - THE WOODLANDS, Texas, March 1, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) will release its fourth quarter and year end 2016 financial results on Friday, March 3, 2017 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the fourth quarter and year end of 2016 at 10:00 a.m. Eastern Time on March 3, 2017. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 80245869. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through April 3, 2017. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.

UPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug

2/28/2017 10:00 pm

[Reuters] - The U.S. Food and Drug Administration said on Tuesday it had approved Lexicon Pharmaceuticals Inc's oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors. The drug, Xermelo or telotristat ethyl, was tested on patients unable to tolerate somatostatin analog therapy (SSA) — the standard-of-care treatment for carcinoid syndrome diarrhea from companies such as Novartis AG and Ipsen SA .

FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug

2/28/2017 09:05 pm

[Reuters] - The U.S. Food and Drug Administration said on Tuesday it had approved Lexicon Pharmaceuticals Inc's oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors. The drug, Xermelo or telotristat ethyl, was tested on patients who were unable to tolerate somatostatin analog therapy (SSA)- the standard-of-care treatment for carcinoid syndrome diarrhea made by companies such as Novartis AG and Ipsen SA.

FDA Approves Lexicon Drug XERMELO™ (telotristat ethyl) 250 mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors

2/28/2017 08:05 pm

[PR Newswire] - THE WOODLANDS, Texas, Feb. 28, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy[i]. Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors (mNETs)[ii]. XERMELO targets the overproduction of serotonin inside mNET cells[iii], providing a new treatment option for patients suffering from carcinoid syndrome diarrhea. "Today's approval of XERMELO represents a shift in the treatment paradigm of carcinoid syndrome diarrhea for cancer patients who are inadequately controlled by SSA therapy, and until now, have had limited options to manage this debilitating condition," said Lonnel Coats, Lexicon's president and chief executive officer.

Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference

2/13/2017 09:00 pm

[PR Newswire] - THE WOODLANDS, Texas, Feb. 13, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 3:30 p.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.